IRON CHELATION THERAPY IMPROVES HAEMATOLOGICAL RESPONSE IN HIGH-RISK MYELODYSPLASTIC PATIENTS TREATED WITH AZACITIDINE

被引：0
|
作者：
Villa, M. R. [1 ]
Gagliardi, A. [1 ]
Della Cioppa, P. [1 ]
Esposito, M. [1 ]
Lucania, A. [1 ]
Izzo, G. Nitrato [1 ]
Improta, S. [1 ]
Mastrullo, L. [1 ]
机构：
[1] ASL Napoli 1 Ctr, UOC Ematol PO San Gennaro, Naples, Italy
来源：
HAEMATOLOGICA | 2016年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P111
引用
收藏
页码：S120 / S121
页数：2
相关论文
共 50 条
  • [41] Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice
    Emilia Scalzulli
    Matteo Molica
    Danilo Alunni Fegatelli
    Gioia Colafigli
    Lorenzo Rizzo
    Marco Mancini
    Fabio Efficace
    Roberto Latagliata
    Robin Foà
    Massimo Breccia
    Annals of Hematology, 2019, 98 : 1919 - 1925
  • [42] Iron chelation therapy in patients with transfusion-dependent myelodysplastic syndrome
    Mast, Alan E.
    Field, Joshua J.
    TRANSFUSION, 2012, 52 (10) : 2078 - 2080
  • [43] Azacitidine Treatment in High Risk Myelodysplastic Patients in Complete Haematological Remission Reverts Mesenchymal Stem Cells to a Normal Phenotype
    Poloni, Antonella
    Maurizi, Giulia
    Mattiucci, Domenico
    Costantini, Benedetta
    Mariani, Marianna
    Mancini, Stefania
    Fanelli, Mirco
    Olivieri, Attilio
    Leoni, Pietro
    BLOOD, 2014, 124 (21)
  • [44] Improved survival in myelodysplastic syndromes patients receiving iron chelation therapy
    Leitch, H. A.
    LEUKEMIA RESEARCH, 2007, 31 : S15 - S15
  • [45] Iron chelation therapy in patients with myelodysplastic syndromes: Consensus conference guidelines
    Mittelman, Moshe
    Lugassy, Gilles
    Merkel, Drorit
    Tamary, Hannah
    Sarid, Nadav
    Rachmilewitz, Eliezer
    Hershko, Chaim
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2008, 10 (05): : 374 - 376
  • [46] Azacitidine Post-transplant Maintenance Improves Disease Progression in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome
    Pasvolsky, Oren
    Saliba, Rima M.
    Popat, Uday R.
    Alousi, Amin
    Mehta, Rohtesh
    Yeh, Jason
    Al-Atrash, Gheath
    Adeel, Masood
    Ramdial, Jeremy
    Marin, David
    Rondon, Gabriela
    Kebriaei, Partow
    Champlin, Richard
    Daver, Naval
    Dinardo, Courtney
    Short, Nicholas J.
    Shpall, Elizabeth J.
    Oran, Betul
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (05): : e196 - e204
  • [47] GLOBAL DNA METHYLATION PREDICTS THE RESPONSIVENESS TO AZACITIDINE IN HIGH-RISK MYELODYSPLASTIC SYNDROMES
    Poloni, A.
    Goteri, G.
    Zizzi, A.
    Serrani, F.
    Costantini, B.
    Trappolini, S.
    Mariani, M.
    Leoni, P.
    HAEMATOLOGICA, 2012, 97 : 133 - 133
  • [48] Review of azacitidine trials in Intermediate-2-and High-risk myelodysplastic syndromes
    Fenaux, Pierre
    Ades, Lionel
    LEUKEMIA RESEARCH, 2009, 33 : S7 - S11
  • [49] Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromes
    Garcia, Jacqueline S.
    Platzbecker, Uwe
    Odenike, Olatoyosi
    Fleming, Shaun
    Fong, Chun Yew
    Borate, Uma
    Jacoby, Meagan A.
    Nowak, Daniel
    Baer, Maria R.
    Peterlin, Pierre
    Chyla, Brenda
    Wang, Huipei
    Ku, Grace
    Hoffman, David
    Potluri, Jalaja
    Garcia-Manero, Guillermo
    BLOOD, 2025, 145 (11) : 1126 - 1135
  • [50] Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload
    Gattermann, Norbert
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2008, 88 (01) : 24 - 29
12345